Ovarian cancer vaccine (Life Research Technologies)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameOvarian cancer vaccine (Life Research Technologies)

Drug Alias NameAutologous TERT-mRNA survivin peptide-loaded dendritic cell vaccine - CELLMED卵巢癌疫苗 - Life Research TechnologiesTERT-mRNA and survivin-peptide double loaded dendritic cellsProcure

ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine

Mechanisms of ActionCD4-positive T-lymphocytes stimulantsCD8-positive T-Lymphocytes stimulants

TargetsNot applicable

Therapy Area/IndicationsOvarian NeoplasmsCarcinoma, Ovarian Epithelial

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryHungaryAustria

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesLife Research Technologies

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesLife Research Technologies Invitrogen Gmbh

Active IndicationsN/A

Inactive IndicationsOvarian NeoplasmsCarcinoma, Ovarian Epithelial

Other Information

ATC CodeN/A